Delivery Order SPE2DR25D3005-SPE2DR26FP7FM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through open procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $3,700.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL. The contract, with an ultimate completion date of November 7, 2025, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This award involved no set-aside designation and was competitively awarded. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a delivery order valued at $10,518.78 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL on November 3, 2025, with completion scheduled for November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a leading biopharmaceutical product used to treat various autoimmune and inflammatory...
- The Defense Logistics Agency awarded a $4,852.12 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a $36,425.77 delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40mg/4ml (2 units) under a firm fixed price contract. This delivery order, issued on October 27, 2025, with an ultimate completion date of November 24, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been selected to fulfill this medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $2,321.40 to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat various inflammatory conditions. This firm fixed-price delivery order, with an ultimate completion date of November 12, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $18,127.20 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 24, 2025, issued on September 23, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $4,531.80 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on November 3, 2025, with an ultimate completion date of November 4, 2025. This contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was awarded competitively. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP7FMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,183.92 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on November 14, 2025, with an ultimate completion date of November 17, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The pharmaceutical will be sourced from the vendor's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and a major distribution hub for federal medical procurement. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through its extensive portfolio of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 11/14/25 |